Insulet Corporation (PODD) Company Profile & Statistics

Insulet Corporation
PODD
(Nasdaq - US)
Closed
267.84
+22.86 (+9.33%)
in:usd•As of: Nov 08, 2024 15:59 UTC -5
Open
256.26
High
275.61
Low
256.26

About Insulet Corporation

CEO

James R. Hollingshead

Headquarters

100 nagog park

acton, ma 01720, united states

Auditor

Grant Thornton LLP

Employees

3,000

Share Holders

Website

www.insulet.com

Industry

medical specialties

Sector

health technology

Company Overview

Insulet Corporation is a leading developer, manufacturer and marketer of the Omnipod Insulin Management System. The system is equipped with a self-adhesive, small and lightweight disposable tubeless Omnipod device along with the wireless and handheld Personal Diabetes Manager (PDM). The Omnipod System is an innovative, discreet and easy-to-use continuous insulin delivery system for people with insulin-dependent diabetes. The Omnipod System consists of Omnipod Insulin Management System ('Omnipod') and the Omnipod DASH Insulin Management System - Insulet's next generation digital mobile Omnipod platform. Insulet has tied up with pharmaceutical and biotechnological companies using customized form of the Omnipod System to deliver a drug at a certain administered volume and over a specified period of time. Insulet has partnered with pharmaceutical and biotechnology companies to tailor the Omnipod System technology platform for the delivery of subcutaneous drugs across other therapeutic areas.

Insulet Corporation Statistics

Valuation Measures

Market Capitalization ²	18.78B
Enterprise Value	19.36B
Enterprise Value/EBITDA (ttm)	55.59
Price to Earnings Ratio (ttm)	70.59
Price to Book (mrq)	16.79
Price to Sales (ttm)	8.96
Price to Cash (ytd)	63.06

Profitability

Gross Margin (ttm)	68.96%
Operating Margin (ttm)	12.84%
Profit Margin (ttm)	20.63%
Return on Equity (ttm)	30.73%
Return on Invested Capital (ttm)	17.93%
Return on Assets (ttm)	9.10%

Income Statement

Revenue (ttm)	1.87B
Revenue Per Share (ttm)	26.71
Gross Profit (ttm)	1.29B
EBITDA (ttm)³	348.20M
Net Income Avi to Common (ttm)	395.30M
Diluted EPS (ttm)	5.50

Share Statistics

Beta (5Y Monthly)	1.22
52-Week Change	72.83%
S&P500 52-Week Change	36.80%
S&P500 Member	Yes
Stock Optionable	Yes
Total Shares Outstanding ¹	70.12M
Dividend Yield	0.00%
Float ⁴	69.78M
% Held by Insiders	0.47%
% Held by Institutions	N/A

Balance Sheet

Total Cash (mrq)	821.00M
Total Cash Per Share (mrq)	11.71
Total Debt (mrq)	1.40B
Total Debt/Equity (mrq)	140.00%
Current Ratio (mrq)	3.60%
Quick Ratio (mrq)	2.71%
Book Value Per Share (mrq)	14.24

Cash Flow

Operating Cash Flow Per Share (ytd)	2.49
Free Cash Flow (ytd)	139.50M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. Stock price provided by Xignite. All numbers are rounded to the closest decimal.

¹ Total Shares outstanding is taken from the most recently filed quarterly or annual report.

² Market Cap is calculated using total shares outstanding and the most recent share price.

³ EBITDA is calculated using methodology that may differ from that used by a company in its reporting.

⁴ The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

Insulet Corporation

Trade With A Regulated Broker